The Enbrel biosimilar, which is branded as Erelzi ... and could free up cash in the US health system that could be spent on newer drugs as well as widening access to biologic medicines.
The drugs are Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara, and the insulins Fiasp and NovoLog. Medicare will announce the next 15 drugs by Feb. 1 and ...
As more United States drug price changes have come to light this month, it remains clear that companies are tamping down ...
Among the first 10 drugs selected for price negotiations under the 2022 Inflation Reduction Act, cardiometabolic medications ...
Medicare beneficiaries may pay less for 15 additional prescription drugs as early as 2027 as part of the next round of federal regulators' price negotiations with pharmaceutical manufacturers.
The second round of Medicare Part D price negotiations will feature two drugs familiar to rheumatologists — Ofev and Otezla — ...
The drugs are Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara, and the insulins Fiasp and NovoLog. Medicare will announce the next 15 drugs by Feb. 1 and negotiate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback